FLT3

Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial

L: English
Watch German version

At the 60th American Society of Hematology (ASH) Annual Meeting, Andreas Burchert from the University of Marburg, Germany, discusses the study findings of the Sormain trial, which is evaluating sorafenib as maintenance therapy after allogeneic stem cell transplantation for patients with FLT3-ITD–positive acute myeloid leukemia.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!